En Attendant Centiloid
Victor L. Villemagne, Vincent Doré, Paul Yates, Belinda Brown, Rachel Mulligan, Pierrick Bourgeat, Robyn Veljanoski, Stephanie R. Rainey-Smith, Kevin Ong, Alan Rembach, Robert Williams, Samantha C. Burnham, Simon M. Laws, Olivier Salvado, Kevin Taddei, S. Lance Macaulay, Ralph N. Martins, David Ames, Colin L. Masters, Christopher C. Rowe
Advances in Research · pp. 723–729 · Published 8 Jul 2014
10.9734/AIR/2014/11599Abstract
Aims: Test the robustness of a linear regression transformation of semiquantitative values from different Aβ tracers into a single continuous scale. Study Design: Retrospective analysis. Place and Duration of Study: PET imaging data acquired in Melbourne and Perth, Australia, between August 2006 and May 2014. Methodology: Aβ imaging in 633 participants was performed with four different radiotracers: flutemetamol (n=267), florbetapir (n=195), florbetaben (n=126) and NAV4694 (n=45). SUVR were generated with the methods recommended for each tracer, and classified as high (Aβ+) or low (Aβ-) based on their respective thresholds. Linear regression transformation based on reported head-to-head comparisons of each tracer with PiB was applied to each tracer result. Each tracer native classification was compared with the classification derived from the transformed data into PiB-like SUVR units (or BeCKeT: Before the Centiloid Kernel Transformation) using 1.50 as a cut-off. Results: Misclassification after transformation to PiB-like SUVR compared to native classification was extremely low with only 3/267 (1.1%) of flutemetamol, 1/195 (0.5%) of florbetapir, 1/45 (2.2%) of NAV4694, and 1/126 (0.8%) of florbetaben cases assigned into the wrong category. When misclassification occurred (<1% of all cases) it was restricted to an extremely narrow margin (±0.02 BeCKeT) around the 1.50 BeCKeT threshold. Conclusion: While a definitive transformation into centesimal units is being established, application of linear regression transformations provide an interim, albeit robust, way of converting results from different Aβ imaging tracers into more familiar PiB-like SUVR units.
References (15)
- 1 Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study [DOI]
- 2 The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease [DOI]
- 3 Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study [DOI]
- 4 In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18) [DOI]
- 5 Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism [DOI]
- 6 18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial [DOI]
- 7 Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods [DOI]
- 8 Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers [DOI]
- 9 Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia [DOI]
- 10 Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease [DOI]
- 11 The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias [DOI]
- 12 Biomarkers for Early Detection of Alzheimer Pathology [DOI]
- 13 18F-florbetaben Aβ imaging in mild cognitive impairment [DOI]
- 14 IC‐O3–01: The Centiloid Scale: Standardization of amyloid imaging measures [DOI]
- 15 O1‐02‐03: Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (18F‐AV‐45): imaging to histopathologic correlations in an end‐of‐life human subject study [DOI]
Cited by 72
Parwi, B Pudjiasmanto, D Purnomo · Journal of Physics: Conference Series · 2017
Christa Dang, Karra D. Harrington, Yen Ying Lim · Journal of Alzheimer’s Disease · 2018
Belinda M. Brown, Stephanie R. Rainey-Smith, Vincent Dore · Journal of Alzheimer's Disease · 2018
Louise N. Pivac, Belinda M. Brown, Kelsey R. Sewell · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2024
Tenielle Porter, Samantha C. Burnham, Lidija Milicic · Journal of Alzheimer’s Disease · 2018
Karra D. Harrington, Yen Ying Lim, David Ames · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2017
Kunal Dhiman, Victor L. Villemagne, Christopher Fowler · Biomedicines · 2022
Kunal Dhiman, Victor L. Villemagne, Christopher Fowler · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2022
Steve Pedrini, Pratishtha Chatterjee, Akinori Nakamura · Frontiers in Aging Neuroscience · 2022
Samantha C. Burnham, Christopher C. Rowe, David Baker · Neurology · 2016
Showing 20 of 72 known citations — external sources report more than can currently be individually listed.
Related research
- Regions and Sub-regions Dysfunctions in Alzheimer’s during Rest — shares topic coverage
- An Overview on the Aetiology and Treatment of Alzheimer's Disease — shares topic coverage
- Dementia Diagnosis and Alternate Treatment: A Recent Update on Treatment Options — shares topic coverage
- The Brain Cholinergic System in Neurodegenerative Diseases — shares topic coverage
- Synthesis and Development of BACE 1 Inhibitor for Alzheimer’s Diseases from Medicinal Plants — shares topic coverage
Article metrics
Real usage data collected on this platform.
88
Page views
0
PDF downloads
30
Outbound clicks
72
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.